Catalyst Funds Management Pty Ltd Increases Stock Position in DaVita Inc. (NYSE:DVA)

Catalyst Funds Management Pty Ltd boosted its holdings in DaVita Inc. (NYSE:DVA) by 77.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,800 shares of the company’s stock after buying an additional 2,100 shares during the period. Catalyst Funds Management Pty Ltd’s holdings in DaVita were worth $718,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of DVA. Franklin Resources Inc. grew its position in shares of DaVita by 134.6% in the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company’s stock valued at $8,885,000 after purchasing an additional 31,502 shares in the last quarter. FMR LLC increased its position in shares of DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after buying an additional 154,061 shares during the period. Atom Investors LP purchased a new stake in shares of DaVita in the third quarter worth about $4,094,000. Assenagon Asset Management S.A. boosted its position in shares of DaVita by 201.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company’s stock valued at $11,159,000 after acquiring an additional 49,885 shares during the period. Finally, Neo Ivy Capital Management purchased a new position in DaVita during the third quarter valued at approximately $726,000. Institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the subject of several analyst reports. Barclays raised their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. Finally, Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $166.33.

DaVita Trading Up 1.7 %

Shares of DVA stock opened at $143.56 on Friday. The business has a 50-day moving average price of $158.92 and a two-hundred day moving average price of $157.62. DaVita Inc. has a 12-month low of $125.64 and a 12-month high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm has a market cap of $11.48 billion, a P/E ratio of 13.37, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last released its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Equities analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.